Severe left ventricular hypertrophy 1 year after transplant predicts mortality in cardiac transplant recipients

被引:34
作者
Goodroe, Randy
Bonnema, D. Dirk
Lunsford, Shayna
Anderson, Phillip
Ryan-Baille, Barbara
Uber, Walt
Ikonomidis, John
Crumbley, Arthur J.
VanBakel, Adrian
Zile, Michael R.
Pereira, Naveen
机构
[1] Med Univ S Carolina, Div Cardiol, Dept Med, Charleston, SC 29425 USA
[2] Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA
[3] Med Univ S Carolina, Div Transplant Surg, Dept Surg, Charleston, SC 29425 USA
[4] Med Univ S Carolina, Transplant Serv, Charleston, SC 29425 USA
[5] Med Univ S Carolina, Dept Pharm Serv, Charleston, SC 29425 USA
[6] Med Univ S Carolina, Div Cardiothorac Surg, Dept Surg, Charleston, SC 29425 USA
关键词
D O I
10.1016/j.healun.2006.11.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Left ventricular hypertrophy (LVH) is a known predictor of morbidity and mortality in patients with essential hypertension. The prevalence and significance of LVH in heart transplant recipients is unknown. Methods: Transthoracic echocardiograms were performed as part of a routine protocol I year after heart transplantation in 141 consecutive patients. Demographic and echocardiographic data were collected using patients' records and center-specific data from the Cardiac Transplant Research Database and analyzed to determine the prevalence and predictors of LVH at 1 year posttransplantation. Patients were divided into three groups based on left ventricular mass (LVM): normal (LVM < 150 g); mild-moderate LVH (LVM 150 to 250 g); and severe LVH (LVM > 250 g). Results: LVH was common at 1 year after heart transplantation, present in 83% of heart transplant recipients. Univariate predictors of severe LVH were increased body mass index (p < 0.01), pre-transplant diabetes mellitus (p = 0.02) and pre-transplant hypertension (p = 0.01). By multivariate analysis, pre-transplant hypertension was the only independent predictor of severe LVH (hazard ratio [HR] 2.3, 95% confidence interval [CI] 1.1 to 5.4,p = 0.05). Heart transplant recipients with severe LVH had significantly decreased survival, as compared to patients with normal LVM and mild-moderate LVH (P = 0.03). After multivaniate analysis adjusting for age, race, gender, pre-transplant hypertension and diabetes, severe LVH remained a strong, independent predictor of mortality (HR 3.6, 95% CI 1.0 to 12.1, P = 0.04). Conclusions: LVH is common at 1 year after heart transplantation and is a strong, independent predictor of increased mortality. Hypertension before transplantation is an independent predictor of the presence of severe LVH at 1 year after heart transplantation.
引用
收藏
页码:145 / 151
页数:7
相关论文
共 32 条
[1]   REGRESSION OF LEFT-VENTRICULAR HYPERTROPHY IN HYPERTENSIVE HEART-TRANSPLANT RECIPIENTS TREATED WITH ENALAPRIL, FUROSEMIDE, AND VERAPAMIL [J].
ANGERMANN, CE ;
SPES, CH ;
WILLEMS, S ;
DOMINIAK, P ;
KEMKES, BM ;
THEISEN, K .
CIRCULATION, 1991, 84 (02) :583-593
[2]  
Billingham M E, 1990, J Heart Transplant, V9, P587
[3]   Marked left ventricular hypertrophy in children on tacrolimus (FK506) after orthotopic liver transplantation [J].
Chang, RKR ;
Alzona, M ;
Alejos, J ;
Jue, K ;
McDiarmid, SV .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (10) :1277-+
[4]  
CZERSKA B, 1991, Ethnicity and Disease, V1, P335
[5]   Link of nonhemodynamic factors to hemodynamic determinants of left ventricular hypertrophy [J].
de Simone, G ;
Pasanisi, F ;
Contaldo, F .
HYPERTENSION, 2001, 38 (01) :13-18
[6]   Prognostic significance of left ventricular mass change during treatment of hypertension [J].
Devereux, RB ;
Wachtell, K ;
Gerdts, E ;
Boman, K ;
Nieminen, MS ;
Papademetriou, V ;
Rokkedal, J ;
Harris, K ;
Aurup, P ;
Dahlöf, B .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (19) :2350-2356
[7]   PERFORMANCE OF PRIMARY AND DERIVED M-MODE ECHOCARDIOGRAPHIC MEASUREMENTS FOR DETECTION OF LEFT-VENTRICULAR HYPERTROPHY IN NECROPSIED SUBJECTS AND IN PATIENTS WITH SYSTEMIC HYPERTENSION, MITRAL REGURGITATION AND DILATED CARDIOMYOPATHY [J].
DEVEREUX, RB ;
CASALE, PN ;
KLIGFIELD, P ;
EISENBERG, RR ;
MILLER, D ;
CAMPO, E ;
ALONSO, DR .
AMERICAN JOURNAL OF CARDIOLOGY, 1986, 57 (15) :1388-1393
[8]   Assessment of myocardial hypertrophy by echocardiography in adult patients receiving tacrolimus or cyclosporine therapy for prevention of acute GVHD [J].
Espino, G ;
Denney, J ;
Furlong, T ;
Fitzsimmons, W ;
Nash, RA .
BONE MARROW TRANSPLANTATION, 2001, 28 (12) :1097-1103
[9]   EFFECT OF SYSTEMIC HYPERTENSION ON RENAL-FUNCTION AND LEFT-VENTRICULAR HYPERTROPHY IN HEART-TRANSPLANT RECIPIENTS [J].
FARGE, D ;
JULIEN, J ;
AMREIN, C ;
GUILLEMAIN, R ;
VULSER, C ;
MIHAILEANU, S ;
DREYFUS, G ;
CARPENTIER, A .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1990, 15 (05) :1095-1101
[10]  
Globits S, 1997, J HEART LUNG TRANSPL, V16, P504